The evidence is mixed on this question.
In the trial that found harm at age 65 and older, the significant increase in dementia risk was in the combined estrogen-progestin arm, while estrogen-alone was not significant on its own, and a meta-analysis of randomized trials found the harm signal was driven by combined therapy, not estrogen alone. But in Finnish registry data, estrogen-only and combined therapy carried similar risk, and the type of progestogen used did not appear to matter. No randomized trial has directly compared micronized progesterone against other progestins on brain outcomes, so this remains an open question rather than a settled one.
One reading of the randomized trial data blames the progestogen for the brain harm seen at older ages; the largest registry data do not support that clean split, and no trial has tested micronized progesterone against synthetic progestins head to head on brain outcomes.
What the research shows, and which source each finding rests on
In the trial of women 65 or older, the significant dementia harm was in the combined CEE plus MPA arm (HR 2.05); the estrogen-alone arm was not significant on its own (HR 1.49), though pooling both per the original protocol reached significance (HR 1.76).
A meta-analysis of randomized trials found dementia harm was driven by estrogen plus progestogen (RR 1.64), with no significant effect from estrogen-only (RR 1.19).
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
combined therapy carries the cognitive risk, estrogen alone is neutral or protective
researchers reading the randomized trial and meta-analysis data this way, including Avrum Bluming in his clinical commentary
Across both the original 65-plus trial and the pooled meta-analysis, the significant dementia signal tracks with the progestin-containing arm, not the estrogen-only arm, suggesting the progestin, not the estrogen, may explain much of the harm.
the estrogen-only versus combined split is not consistent enough to blame or absolve either component
researchers behind the Finnish registry analysis
In their nationwide data, estrogen-only and combined therapy carried similar risk, and which specific progestogen was used made no difference, undercutting a simple story where the progestin alone is the problem.
What would settle it: A head-to-head randomized comparison of progestogens with brain biomarker endpoints, and large observational analyses that separately track progestogen type with modern formulations.
What is really going on here
- Which formulation and route does this specific claim cover?
- Has this specific regimen actually been compared to another in a trial, or is this an inference from indirect data?
Questions for your doctor
- What specific hormone and progestogen combination are you recommending, and why?
- Is there a reason to prefer micronized progesterone over another progestogen in my case?
- How much of the current evidence on this question is from trials versus observational data?
Questions with no answer yet
Is it specifically the progestin, rather than estrogen, that drives the dementia signal seen in older trial participants?
Partly studiedWhat is known: In the randomized trial that found harm in women 65 and older, the significant increase was in the combined estrogen-progestin arm, and a meta-analysis found the harm driven by combined therapy rather than estrogen alone. But registry data from another country found estrogen-only and combined therapy carried similar risk, with no difference by which specific progestogen was used, so the two evidence bases disagree.
What would test it: A head-to-head randomized comparison of progestogens, ideally micronized progesterone against a synthetic progestin, with brain biomarker endpoints.
Has anyone ever tested micronized progesterone specifically, rather than the older synthetic progestin used in the original large trial, for brain outcomes?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The one trial in recently menopausal women that used micronized progesterone found neither cognitive harm nor benefit, but no trial has been designed to compare micronized progesterone against a synthetic progestin head to head on brain endpoints.
What would test it: A randomized trial comparing the two progestogen types directly, with brain imaging or cognitive endpoints as the primary outcome.
Sources
- 1.Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.Shumaker SA et al. (WHIMS), JAMA 2003 · Randomised trial
- 2.Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.Shumaker SA et al., JAMA 2004 · Randomised trial
- 3.Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia.Nerattini M et al., Front Aging Neurosci 2023 · Systematic review or guideline
- 4.Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.Savolainen-Peltonen H et al., BMJ 2019 · Observational study
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Can taking hormone therapy prevent Alzheimer's disease or dementia?
- Is it true that hormone therapy doubles your risk of dementia?
- Does it matter how soon after menopause I start hormone therapy, for my brain?
- Does having early menopause or having my ovaries removed increase my risk of dementia?
- If I carry the APOE4 gene, does that change whether hormone therapy is good or bad for my brain?
- I read a study that said hormone therapy causes dementia, even in women who started young. Is that true?
- Back to topic: Hormone therapy and the brain